Merck Raises Outlook Following Tax Rate Benefit and Rapid Drug Scaling
Yahoo Finance ·
Merck shares climbed about 5 percent during Thursday morning trading as the pharmaceutical giant lifted its financial outlook. Third-quarter revenue advanced 5 percent compared to the prior year to reach approximately $18.1 billion, though management noted that about $550 million of this expansion stemmed from the timing of customer orders. Excluding this buying shift, top-line growth was virtually flat. Generics continue to erode legacy products Januvia and Bridion following the loss of U.S. exclusivity, with Bridion dropping 67 percent. Nevertheless, newer treatments are gaining substantial momentum to offset these headwinds, as Keytruda Qlex sales surged to $830 million and Winrevair skyrocketed 93 percent year-over-year to $694 million. On the bottom line, GAAP earnings per share fell 12 percent to $2.04, while adjusted earnings per share declined 3 percent to $2.49.
AI 시장 분석
Merck reported a 5% increase in Q3 revenue to $18.1 billion, though about $550 million of this was analyzed as a temporary factor due to customer purchasing timing adjustments. The stock rose about 5% in Thursday morning trading, driven by a lower tax rate and an upward revision to guidance. Rapid sales growth of new drugs such as Keytruda and Winrevair is offsetting the sluggishness of older key drugs caused by generic competition.
상승 영향
- Biotechnology — Rapid sales growth of innovative new drugs such as Keytruda and Winrevair was confirmed, and earnings forecasts were raised due to a lower tax rate, which is positive for the stock.
하락 영향
- Pharmaceuticals — The loss of exclusivity for Januvia and Bridion has intensified generic competition impacts, causing Bridion sales to plunge 67%, which is a burden on mid-to-long-term earnings.
DYAX 전담 분석
Merck's Q3 adjusted EPS was $2.49, down 3% year-over-year, but the annual earnings guidance was revised upward due to the lower tax rate effect. However, excluding the purchasing timing factor, actual revenue growth is minimal, and Bridion sales plummeted 67% due to generic hits from the loss of US exclusivity for Januvia and Bridion.
Future stock performance depends on how sustainably the growth of the new product pipeline can overwhelm temporary revenue distortions and the pace of generic erosion. Investors should closely monitor the base effect from purchasing timing adjustments and the steep sales growth trend of Winrevair in upcoming quarters.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 74% · Bearish (Short) 26%
405 participants
Related News
- Nasdaq Faces Sharp Decline Amid AI Stock Sell-Off Following Sticky Inflation Data
- Why Marvell Technology Could Outperform Nvidia and AMD in the AI Chip Race
- AMD Faces High Expectations as Jefferies Cites Limited Near-Term Upside
- Gene Munster Flags Alphabet Results As A Warning Signal For Amazon Shareholders
- Fortinet Suffers Worst Selloff in Years Despite Strong Third-Quarter Results
- Cognizant Shares Slide as Bookings Fall 7% Despite Top-Line Revenue Gain
